PRESS RELEASE

Obalon Announces Upcoming Conference Presentations

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang, President and Chief Operating Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will participate in the following upcoming investor conferences:

Stifel Healthcare Conference                                                                                

Wednesday, November 14, 2018, Presentation at 1:15pm ET
Lotte New York Palace Hotel, New York City
Webcast Available at: http://wsw.com/webcast/stifel14/obln/

Canaccord Genuity Medical Technologies & Diagnostics Forum

Thursday, November 15, 2018, Presentation at 1:30pm ET                                                             
Westin Grand Central Hotel, New York City         
Webcast Available at: http://wsw.com/webcast/canaccord32/obln/

Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit http://www.obalon.com/.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com

Obalon_Logo_Teal_2c.jpg

Source: Obalon Therapeutics, Inc.

IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling